The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel

Abstract

Bisphosphonates are well established in the management of breast-cancer-induced bone disease. Recent studies have suggested that these compounds are effective in preventing the development of bone metastases. However, it is unclear whether this reflects an indirect effect via an inhibition of bone resorption or a direct anti-tumour effect. The breast cancer cell lines, MCF-7 and MDA-MB-231 cells were treated with increasing concentrations of the bisphosphonate, zoledronic acid, for varying time periods, in the presence or absence of paclitaxel. The effects of zoledronic acid were determined by assessing cell number and rate of apoptosis by evaluating changes in nuclear morphology and using a fluorescence nick translation assay. Zoledronic acid caused a dose- and time-dependent decrease in cell number (P< 0.001) and a concomitant increase in tumour cell apoptosis (P< 0.005). Short-term exposure to zoledronic acid was sufficient to cause a significant reduction in cell number and increase in apoptosis (P< 0.05). These effects could be prevented by incubation with geranyl geraniol, suggesting that zoledronic acid-induced apoptosis is mediated by inhibiting the mevalonate pathway. Treatment with zoledronic acid and clinically achievable concentrations of paclitaxel resulted in a 4-5-fold increase in tumour cell apoptosis (P< 0.02). Isobologram analysis revealed synergistic effects on tumour cell number and apoptosis when zoledronic acid and paclitaxel were combined. Short-term treatment with zoledronic acid, which closely resembles the clinical setting, has a clear anti-tumour effect on breast cancer cells. Importantly, the commonly used anti-neoplastic agent, paclitaxel, potentiates the anti-tumour effects of zoledronic acid. These data suggest that, in addition to inhibiting bone resorption, zoledronic acid has a direct anti-tumour activity on breast cancer cells in vitro.

References 31

1. 1.

   Aparicio A., Gardner A., Tu Y., Savage A., Berenson J., Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia. 1998;12(2):220-229.

   Not in our library10.1038/sj.leu.2400892

2. 2.

   Berenbaum M. C. What is synergy? Pharmacol Rev. 1989;41(2):93-141.

   Not in our library

3. 3.

   Berenson J. R., Lichtenstein A., Porter L., Dimopoulos M. A., Bordoni R., George S., Lipton A., Keller A., Ballester O., Kovacs M. J. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996;334(8):488-493.

   Not in our library10.1056/nejm199602223340802

4. 4.

   Boissier S., Magnetto S., Frappart L., Cuzin B., Ebetino F. H., Delmas P. D., Clezardin P. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 1997;57(18):3890-3894.

   Not in our library

5. 5.

   Coxon F. P., Benford H. L., Russell R. G., Rogers M. J. Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs. Mol Pharmacol. 1998;54(4):631-638.

   Not in our library

6. 6.

   Derenne S., Amiot M., Barillé S., Collette M., Robillard N., Berthaud P., Harousseau J. L., Bataille R. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res. 1999;14(12):2048-2056.

   Not in our library10.1359/jbmr.1999.14.12.2048

7. 7.

   Diel I. J., Solomayer E. F., Costa S. D., Gollan C., Goerner R., Wallwiener D., Kaufmann M., Bastert G. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998;339(6):357-363.

   Not in our library10.1056/nejm199808063390601

8. 8.
   Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro · 1999

   Not checked
9. 9.

   Frith J. C., Mönkkönen J., Blackburn G. M., Russell R. G., Rogers M. J. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res. 1997;12(9):1358-1367.

   Not in our library10.1359/jbmr.1997.12.9.1358

10. 10.

    Fromigue O., Lagneaux L., Body J. J. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res. 2000;15(11):2211-2221.

    Not in our library10.1359/jbmr.2000.15.11.2211

11. 11.

    Gorczyca W., Melamed M. R., Darzynkiewicz Z. Apoptosis of S-phase HL-60 cells induced by DNA topoisomerase inhibitors: detection of DNA strand breaks by flow cytometry using the in situ nick translation assay. Toxicol Lett. 1993;67(1-3):249-258.

    Not in our library10.1016/0378-4274(93)90060-b

12. 12.

    Greco W. R., Bravo G., Parsons J. C. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev. 1995;47(2):331-385.

    Not in our library

13. 13.

    Hortobagyi G. N., Theriault R. L., Porter L., Blayney D., Lipton A., Sinoff C., Wheeler H., Simeone J. F., Seaman J., Knight R. D. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996;335(24):1785-1791.

    Not in our library10.1056/nejm199612123352401

14. 14.

    Hughes D. E., Wright K. R., Uy H. L., Sasaki A., Yoneda T., Roodman G. D., Mundy G. R., Boyce B. F. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995;10(10):1478-1487.

    Not in our library10.1002/jbmr.5650101008

15. 15.

    Kanis J. A., Powles T., Paterson A. H., McCloskey E. V., Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone. 1996;19(6):663-667.

    Not in our library10.1016/s8756-3282(96)00285-2

16. 16.

    Leonessa F., Jacobson M., Boyle B., Lippman J., McGarvey M., Clarke R. Effect of tamoxifen on the multidrug-resistant phenotype in human breast cancer cells: isobologram, drug accumulation, and M(r) 170,000 glycoprotein (gp170) binding studies. Cancer Res. 1994;54(2):441-447.

    Not in our library

17. 17.

    Luckman S. P., Hughes D. E., Coxon F. P., Graham R., Russell G., Rogers M. J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998;13(4):581-589.

    Not in our library10.1359/jbmr.1998.13.4.581

18. 18.

    Magnetto S., Boissier S., Delmas P. D., Clezardin P. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer. 1999;83(2):263-269.

    Not in our library10.1002/(sici)1097-0215(19991008)83:2<263::aid-ijc19>3.0.co;2-t

19. 19.

    McCloskey E. V., MacLennan I. C., Drayson M. T., Chapman C., Dunn J., Kanis J. A. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol. 1998;100(2):317-325.

    Not in our library10.1046/j.1365-2141.1998.00567.x

20. 20.

    O'Connor P. M., Jackman J., Bae I., Myers T. G., Fan S., Mutoh M., Scudiero D. A., Monks A., Sausville E. A., Weinstein J. N. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997;57(19):4285-4300.

    Not in our library

21. 21.

    Paterson A. H., Powles T. J., Kanis J. A., McCloskey E., Hanson J., Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 1993;11(1):59-65.

    Not in our library10.1200/jco.1993.11.1.59

22. 22.

    Rogers M. J., Chilton K. M., Coxon F. P., Lawry J., Smith M. O., Suri S., Russell R. G. Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. J Bone Miner Res. 1996;11(10):1482-1491.

    Not in our library10.1002/jbmr.5650111015

23. 23.

    Saarto T., Blomqvist C., Virkkunen P., Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol. 2001;19(1):10-17.

    Not in our library10.1200/jco.2001.19.1.10

24. 24.

    Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D. D., Golub E., Rodan G. A. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991;88(6):2095-2105.

    Not in our library10.1172/jci115539

25. 25.

    Shipman C. M., Croucher P. I., Russell R. G., Helfrich M. H., Rogers M. J. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res. 1998;58(23):5294-5297.

    Not in our library

26. 26.

    Shipman C. M., Rogers M. J., Apperley J. F., Russell R. G., Croucher P. I. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol. 1997;98(3):665-672.

    Not in our library10.1046/j.1365-2141.1997.2713086.x

27. 27.

    Theriault R. L., Lipton A., Hortobagyi G. N., Leff R., Glück S., Stewart J. F., Costello S., Kennedy I., Simeone J., Seaman J. J. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol. 1999;17(3):846-854.

    Not in our library10.1200/jco.1999.17.3.846

28. 28.

    Wilson W. H., Berg S. L., Bryant G., Wittes R. E., Bates S., Fojo A., Steinberg S. M., Goldspiel B. R., Herdt J., O'Shaughnessy J. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol. 1994;12(8):1621-1629.

    Not in our library10.1200/jco.1994.12.8.1621

29. 29.

    Wyllie A. H., Kerr J. F., Currie A. R. Cell death: the significance of apoptosis. Int Rev Cytol. 1980;68:251-306.

    Not in our library10.1016/s0074-7696(08)62312-8

30. 30.

    Yoneda T., Michigami T., Yi B., Williams P. J., Niewolna M., Hiraga T. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer. 2000;88(12 Suppl):2979-2988.

    Not in our library10.1002/1097-0142(20000615)88:12+<2979::aid-cncr13>3.0.co;2-u

31. 31.

    van der Pluijm G., Vloedgraven H., van Beek E., van der Wee-Pals L., Löwik C., Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest. 1996;98(3):698-705.

    Not in our library10.1172/jci118841

Cited by papers we hold 5

• Targeting SREBP-2-Regulated Mevalonate Metabolism for Cancer Therapy · 2020
  No notice
• Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells · 2017
  Not checked
• Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial · 2009
  No notice
• Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro · 2003
  No notice
• New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects · 2003
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.